The patient similarity is a way to use medical data sets to integrate multiple data types to facilitate medical decision-making. While individualized data-driven clinical analysis is still developing, patient similarity networks can facilitate research. Moreover, patient similarity solutions are crucial to innovative targeted drug trials, overcoming drug resistance, and combining therapies. Patient similarity networks development is crucial in the case of hydroxychloroquine, as it has got negative coverage due to adverse events when treating patients with COVID-19 pneumonia for emergency use. Our client wanted us to define whether hydroxychloroquine is safe for patients with rheumatoid arthritis (at the age of 18 years or older).
As a result, we defined that hydroxychloroquine treatment is safe for patients with rheumatoid arthritis in the short term but might be associated with cardiovascular mortality in the long term.